The Magazine for Sleep Professionals
Tuesday, July 28, 2026
Takeda China announced that the National Medical Products Administration of China has approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1) in adolescents aged 16 years and older and adults. Oveporexton is the first oral orexin receptor 2 (OX2R)-selective agonist approved in China and is the […]
The 40th annual SLEEP meeting drew its usual crowd of clinicians, researchers, technologists, and industry representatives to Baltimore — but this year’s meeting felt different in at least one important way. The pharmaceutical presence on the exhibit floor and in sponsored symposia has grown substantially over the past decade, and […]
